Results of phase III trial of lebrikizumab in moderate-to-severe AD at 52 weeks, A. Blauvelt et al.
HTML-код
- Опубликовано: 20 янв 2025
- Author video for 'Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials'
Full article: doi.org/10.109...